Stereotaxis has announced that the first patients have been successfully treated utilising Abbott’s EnSite X EP system with Stereotaxis’ robotic magnetic navigation system.
The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the precision and stability of robotics during therapy delivery, the companies said in a press release. The integration of these technologies was announced at the Heart Rhythm Society 2023 annual meeting (19–21 May, New Orleans, USA).
The first integrated procedures were successfully conducted by Sing-Chien Yap and Tamas Szili-Torok at Erasmus Medical Center in Rotterdam, The Netherlands, and by Burkhard Hügl at Marienhaus St. Elisabeth Hospital in Neuwied, Germany.
“The integration of advanced mapping with the precision and safety of robotics helps provide the best therapy for patients and an enhanced workflow for physicians,” said Sing-Chien Yap. “These pioneering integrated robotic EnSite X procedures went very well, with successful treatment of patients with atrial and ventricular arrhythmias in a safe and efficient fashion.”
“We have long championed the benefits of open interoperability in electrophysiology as a way to pair the most suitable technologies for each patient,” added Tamas Szili-Torok. “Full integrated use of EnSite X with Stereotaxis robotic technology worked smoothly and we are delighted to contribute to this progress.”
“The community of physicians who are pioneering robotics in electrophysiology have long championed increased integrations,” said Burkhard Hügl. “The integration of both systems enables me to address the most complex arrhythmia patients. I am very pleased with this technological advance and the growing recognition that robotics plays an important role for the electrophysiology field.”
